Novo invests $6B+ to expand manufacturing facilities as demand for Wegovy skyrockets
Novo Nordisk is investing more than DKK 42 billion ($6 billion) to expand its existing manufacturing facilities in Denmark, mostly to increase its active pharmaceutical ingredients (API) capacity, the company announced Friday.
The facilities in Kalundborg, Denmark, will be able to manufacture multiple products, including GLP-1s, to “meet future market demands” as the demand for its weight loss product, Wegovy, continues to soar. This investment will also boost packaging capacity.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.